Kwality Pharmaceuticals Ltd — Results, 11-08-2025: Result

Kwality Pharmaceuticals' board has approved its financial results for the quarter. The company reported a strong start to FY26, with consolidated revenue rising 39.8% year-on-year to X111.8 crore. EBITDA grew 39% to X24.6 crore, maintaining stable margins. Net profit increased by 43% to X11.9 crore. Operational highlights include a successful Zimbabwe regulatory audit and new product registrations, deepening African market presence. An EU-GMP audit for manufacturing facilities is set for October, aiding European expansion. Preparations for WHO-GMP inspection of its biologics facility and production expansion for Erythropoietin are also underway, supporting the X500 crore FY26 revenue target.